{"product_id":"globusmedical-swot-analysis","title":"Globus Medical SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGlobus Medical shows strong innovation in spinal implants and a scalable commercial footprint, but faces pricing pressure and dependence on North American sales; regulatory shifts and competitor M\u0026amp;A present both risks and opportunities. Discover the full SWOT analysis for detailed, research-backed insights, editable Word and Excel deliverables, and strategic takeaways to inform investment or planning decisions—purchase the complete report to unlock the full picture.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Excelsius Robotics Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExcelsiusGPS and Excelsius3D combine navigation and robotic assistance into one workflow, driving a unified surgical platform that increased Globus Medical’s robotic-assisted procedures by ~38% YoY to ~16,200 cases in 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 deep integration of proprietary software, instruments, and service contracts created high switching costs for hospital systems, with retention rates above 92% in core accounts.\u003c\/p\u003e\n\u003cp\u003eThe ecosystem produced strong pull-through: robots accounted for 22% of implant \u0026amp; consumable revenue in 2025, supporting gross margins near 68% on spinal implants and recurring-consumable growth of 24% YoY.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful NuVasive Integration Synergies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpfollowing the merger globus medical harmonized its engineering culture with nuvasive sales and clinical teams boosting cross-sell or adoption spine procedure market share rose contributing to a combined revenue of about in fy2024.\u003e\n\u003cpthe company captured roughly in run-rate cost synergies by via consolidated manufacturing and admin improving adjusted ebitda margin basis points versus pro forma\u003e\n\u003cpintegration produced one of the broadest musculoskeletal portfolios thoracolumbar mis lateral and motion preservation all surgical approaches increasing addressable market reach to roughly\u003e\n\u003c\/pintegration\u003e\u003c\/pthe\u003e\u003c\/pfollowing\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry Leading Profitability and Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobus Medical posts industry-leading profitability with adjusted EBITDA margins near 26% in FY2024 and free cash flow of $320 million, enabling self-funding of R\u0026amp;D without major debt issuance.\u003c\/p\u003e\n\u003cp\u003eThis cash strength funded $120 million in R\u0026amp;D in 2024 and supports strategic M\u0026amp;A and $200 million share-repurchase capacity, giving investors downside protection versus macro shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid Innovation and Product Lifecycle Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobus Medical moves concepts to market faster than many larger peers, shipping 18 FDA-clearances in 2023 and sustaining a 12% average annual product revenue growth from 2021–2024.\u003c\/p\u003e\n\u003cp\u003eThe in-house R\u0026amp;D pipeline refreshed the spine portfolio with motion-preservation and fixation offerings that lifted spine segment sales to $832 million in FY2024, keeping pace with the shift to minimally invasive surgery.\u003c\/p\u003e\n\u003cp\u003eThe company’s agility shortens time-to-revenue and captures surgeon adoption ahead of bigger rivals, supporting a 2024 gross margin near 72%.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18 FDA clearances in 2023\u003c\/li\u003e\n\u003cli\u003e12% avg. product revenue CAGR 2021–2024\u003c\/li\u003e\n\u003cli\u003e$832M spine sales FY2024\u003c\/li\u003e\n\u003cli\u003e~72% gross margin 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertically Integrated Manufacturing Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGlobus Medical handles a large share of production in-house, giving tight control over quality, cost and inventory and protecting proprietary manufacturing methods.\u003c\/p\u003e\n\u003cp\u003eThis vertical integration reduced supply-chain disruption risk during 2020–2023 and helped Globus report adjusted gross margins around 77% in 2024, above many peers.\u003c\/p\u003e\n\u003cp\u003eCapturing manufacturing value internally has supported higher margins versus rivals using contract manufacturers and preserved pricing flexibility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher gross margin: ~77% (2024)\u003c\/li\u003e\n\u003cli\u003eLower supply-chain exposure: reduced third-party dependency\u003c\/li\u003e\n\u003cli\u003eProtects IP and proprietary processes\u003c\/li\u003e\n\u003cli\u003eImproves inventory and cost control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobotics drive growth: 38% YoY to 16.2k cases; robots=22% of revenue, FCF $320M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegrated robotic platform (ExcelsiusGPS\/3D) drove ~38% YoY rise to ~16,200 robotic cases in 2025; robots were 22% of implant \u0026amp; consumable revenue in 2025. Retention \u0026gt;92% in core accounts; recurring-consumable growth +24% YoY. FY2024 revenue ~$2.4B, spine sales $832M; adjusted EBITDA margin ~26%, FCF $320M; R\u0026amp;D $120M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobotic cases (2025)\u003c\/td\u003e\n\u003ctd\u003e~16,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRobots % revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;92%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue FY2024\u003c\/td\u003e\n\u003ctd\u003e$2.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpine sales FY2024\u003c\/td\u003e\n\u003ctd\u003e$832M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e~26%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF 2024\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Globus Medical, outlining its core strengths and weaknesses, identifying growth opportunities in spine robotics and global expansion, and highlighting external threats like competitive pressure, regulatory challenges, and reimbursement risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOffers a focused Globus Medical SWOT snapshot to quickly align strategy and highlight competitive strengths, weaknesses, opportunities, and threats for fast executive decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrganizational Complexity Post-Merger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2023 merger of Globus Medical and NuVasive created a $6.6B combined revenue base (FY2024 pro forma), adding management layers that often slow decisions; integration meetings increased 28% in 2024 vs 2022 internal benchmarks. \u003c\/p\u003e\n\u003cp\u003eDisparate IT stacks and global logistics remain a 2025 burden—IT consolidation projected to cost $150–200M and delay some SKU fulfillment by 3–6 weeks in APAC. \u003c\/p\u003e\n\u003cp\u003eProcess friction risks slower local responses; market-share loss of 0.3–0.7 percentage points in select EMEA markets tied to rollout delays in H2 2024. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales Force Retention and Attrition Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConsolidating two large sales organizations can create territory overlap and commission changes that risk alienating top reps; industry data shows attrition spikes up to 25% during major reorganizations, and medical device firms report average salesforce churn rising from 12% to ~18% in transition years. Competitors actively recruit during these windows, causing potential revenue leakage in key U.S. and EMEA regions where Globus Medical earned ~70% of 2024 sales. Maintaining a stable, motivated sales force is therefore a critical retention and execution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue Concentration in Spine Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobus Medical still earns roughly 70% of revenue from spinal products (FY2024 revenue $1.55B; spine ~ $1.09B), so dependence on spine surgery leaves results exposed to regulatory shifts, Medicare\/insurance reimbursement cuts, or a disruptive spinal implant innovation.\u003c\/p\u003e\n\u003cp\u003eLimited presence outside orthopedics compared with diversified peers raises volatility: a 10% downturn in spine sales would cut total revenue ~7%—a bigger hit than for multi‑segment healthcare conglomerates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLitigation and Intellectual Property Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGlobus Medical faces frequent, costly IP disputes common in medical devices; legal expenses hit $71 million in 2024, up from $58 million in 2023, squeezing operating margins.\u003c\/p\u003e\n\u003cp\u003eDefending and enforcing patents diverts management time and capital, and injunction risk can delay product launches and revenue recognition.\u003c\/p\u003e\n\u003cp\u003eInvestors see heightened uncertainty: 3 patent suits active at year-end 2024, any adverse ruling could materially affect stock and sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegal spend: $71M (2024)\u003c\/li\u003e\n\u003cli\u003eActive suits: 3 (YE 2024)\u003c\/li\u003e\n\u003cli\u003e2024 margin pressure: gross margin down 120 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Specialized Surgeon Training\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Excelsius GPS platform and complex implant systems demand extensive surgeon training to reach proficiency, creating a market-adoption bottleneck that raises onboarding costs and slows revenue realization.\u003c\/p\u003e\n\u003cp\u003eGlobus Medical spent an estimated $35–40M on clinical education and bioskills labs in 2024, so failure to scale training as new devices roll out could cut expected uptake and delay FY+1 sales growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh training hours per surgeon prolong rollouts\u003c\/li\u003e\n\u003cli\u003e$35–40M education spend in 2024\u003c\/li\u003e\n\u003cli\u003eScaling lag risks slower device adoption and delayed revenues\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration drag risks $1.55B revenue as spine dependence, IT costs, legal and churn bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntegration drag after the 2023 Globus–NuVasive merger raised meetings 28% (2024 vs 2022), with IT consolidation costing $150–200M and SKU delays of 3–6 weeks in APAC; salesforce churn risk up to 25% during reorgs threatens U.S.\/EMEA revenue where ~70% of 2024 sales occurred. Reliance on spine (spine ~$1.09B of $1.55B FY2024) makes revenue sensitive to reimbursement or tech disruption; legal spend rose to $71M (2024) with 3 active suits; training costs $35–40M slow adoption.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$1.55B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpine revenue\u003c\/td\u003e\n\u003ctd\u003e$1.09B (~70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegal spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$71M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive suits (YE2024)\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEducation spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$35–40M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIT consolidation cost (proj)\u003c\/td\u003e\n\u003ctd\u003e$150–200M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC SKU delay\u003c\/td\u003e\n\u003ctd\u003e3–6 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease in meetings\u003c\/td\u003e\n\u003ctd\u003e28% (2024 vs 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGlobus Medical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is not a sample—it’s the real analysis you'll download post-purchase. You’re viewing a live preview of the actual SWOT file; buy now to access the full, editable report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752434151801,"sku":"globusmedical-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/globusmedical-swot-analysis.png?v=1772240948","url":"https:\/\/matrixbcg.com\/products\/globusmedical-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}